The Carpentier-Edwards bioprosthesis: a comparative study analyzing failure rates by age

Area of Science:

• Cardiovascular Surgery
• Biomedical Engineering
• Biostatistics

Background:

• Bioprosthetic valve durability is crucial, especially in middle-aged patients (55-70 years).
• Existing data on valve failure rates is less defined for this specific age group compared to younger or elderly patients.
• The Carpentier-Edwards bioprosthesis is widely used, necessitating an understanding of its long-term performance in diverse age demographics.

Purpose of the Study:

• To determine the failure rate of the Carpentier-Edwards bioprosthesis in middle-aged patients.
• To compare valve failure rates between patients aged 55-69 and those 70 years and older.
• To provide data to aid in prosthesis selection for middle-aged individuals undergoing valve replacement.

Main Methods:

• A retrospective comparative study analyzing Carpentier-Edwards bioprosthesis failure rates.
• Utilized the Wilcoxon (Breslow) statistical technique for actuarial analysis.
• Data collected from 502 patients implanted between September 1978 and December 1986 by a single surgical team.

Main Results:

• Overall 30-day mortality was 8.4%.
• In patients aged 55-69 (Group I), 8 valve failures occurred, with 95.4% of valves free of failure at 5 years and 95% at 7 years.
• In patients aged 70 and above (Group II), only 2 valve failures were recorded.

Conclusions:

• The Carpentier-Edwards bioprosthesis demonstrates a low failure rate in middle-aged patients (55-69 years).
• The findings support the use of this bioprosthesis in the 55-69 age group.
• Further research may refine indications for bioprosthetic valve use across different age strata.